Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -1.75% 56.00p 54.00p 58.00p 56.50p 54.50p 56.50p 103,157 15:14:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 65.57

Angle Share Discussion Threads

Showing 47676 to 47700 of 47700 messages
Chat Pages: 1908  1907  1906  1905  1904  1903  1902  1901  1900  1899  1898  1897  Older
DateSubjectAuthorDiscuss
20/7/2018
13:23
Mirako, The key point about Parsortix is it's ability to "harvest" viable cells for downstream analysis. This is "The Holy Grail" that nobody else has achieved yet.
jelenko
20/7/2018
12:48
Mirako, To my knowledge there are no "target numbers". The below link takes you to the formal objectives etc.of the trial. https://clinicaltrials.gov/ct2/show/NCT03427450
jelenko
20/7/2018
11:40
Does anybody know the cut-off to meet the primary endpoint on the current trial? I.e. do they need 100% sensitivity in capture of CTCs from MBC patients, or is there a lower threshold or no threshold at all? If there's no particular threshold, any thoughts on what would be a problematic level of sensitivity (clearly specificity shouldn't be an issue)? If I understand the Cellsearch FDA studies correctly, 6 out of 231 patients had no CTC results at baseline (97.4% sensitivity).
mirako
20/7/2018
09:55
hTtps://www.forbes.com/sites/victoriaforster/2018/07/19/liquid-biopsy-controversy-rages-on/ Huge variation with current ctDNA tests. Might just play right into the CTC capture players hands. No false positives. Edit: Follows on from the article I posted before
waterloo01
19/7/2018
17:34
Their 2018 sales are likely to be well over $30b
jelenko
19/7/2018
13:35
Interesting thanks
l0ngterm
19/7/2018
13:11
We would be pocket change for them. Massive income.
jelenko
19/7/2018
12:48
Not checked Abbott's financials, but could they buy angle out at some point?
l0ngterm
18/7/2018
13:53
Yes, interesting to see that they received FDA approval for various devices recently and on a fairly frequent basis it seems. Good to have them with us doing their bit in our FDA trial!!
jelenko
18/7/2018
13:42
Good to see Abbott’s results on the up.
semper vigilans
18/7/2018
12:32
I think the upcoming clinical trial progress report and future FDA submission is so important that is makes the F.Y results pretty much academic. We all know what has happened in the last 12 months, that will only be reiterated I'm sure.
jelenko
18/7/2018
12:17
I'm keen to see the latest numbers on the number of machines deployed and number of separations - the last results statement indicated that we should see a decent uplift this time...
miavoce
18/7/2018
11:28
With the results being only a week today l would expect any major update news to be announced then.
mikepompeyfan
18/7/2018
11:06
Delayed admission shouldn't really effect the scheme of things. Hoping for good news soon about FDA uptake.
4legs
18/7/2018
10:18
Thought there might have been an agm statement
morgank
18/7/2018
10:17
Won't cost much more than 100k per annum across all three of them so not a major cash burner - could get 15 of these folks plus change for the price of one CEO ;-)
miavoce
18/7/2018
07:53
I see it as positive myself
jelenko
18/7/2018
07:40
They may not all be new appointments if anyone has left? They will be at the sharp end of progressing research which mustn’t be allowed to stand still if it has decent prospects.
semper vigilans
18/7/2018
07:32
Brave, I would have thought, ahead of any sign at all of material revenue..its one thing spending money to secure the FDA and hopefully gain a licence, but to ramp up the cash burn in this way ahead of clearly identifiable income may be a worry..
bagpuss67
17/7/2018
15:08
Recruiting for 3 more lab positions. Https://angleplc.com/careers/
4legs
17/7/2018
10:52
Angle wants another non-executive director: "Remuneration is c£25k pa for 1 to 2 days per month (formal & informal time) for Board & Sub Committee Meetings. This role will close on 27th July 2018,"
clausentum
17/7/2018
07:55
That may go over the head of the Mail journalist Waterloo! However it does identify other projects and approaches that may or may not become competition to Parsortix. I wonder if there will be a few words from AN tomorrow in addition to the confirmation of the share placement?
semper vigilans
17/7/2018
07:48
ctDNA not all it's made out to be. htTps://www.ncbi.nlm.nih.gov/pubmed/29504847 Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection.
waterloo01
17/7/2018
07:37
going to be a big splash when Parsortix hits the press as the first FDA approved product for this purpose...
bagpuss67
17/7/2018
07:11
htTp://www.dailymail.co.uk/health/article-5959241/A-magnetic-wire-help-doctors-detect-cancer-patients-symptoms-study-declares.html Why collect CTC's non invasively when you can do it via a surgical procedure! (This has only been tested in pigs to date and not licensed to test in humans. Suggest it never will either!
waterloo01
Chat Pages: 1908  1907  1906  1905  1904  1903  1902  1901  1900  1899  1898  1897  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180722 22:02:06